DuraSeal Exact Spine Sealant System Post-Approval Study (DuraSeal PAS)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Arizona
-
Phoenix, Arizona, United States, 85023
-
-
California
-
Los Angeles, California, United States, 90033
-
Sacramento, California, United States, 95616
-
San Francisco, California, United States, 94143
-
San Jose, California, United States, 95128
-
Stanford, California, United States, 94305
-
-
Colorado
-
Boulder, Colorado, United States, 80302
-
Colorado Springs, Colorado, United States, 80907
-
Denver, Colorado, United States, 80045
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20037
-
-
Florida
-
Tampa, Florida, United States, 33606
-
Tampa, Florida, United States, 33637
-
-
Georgia
-
Atlanta, Georgia, United States, 30303
-
-
Illinois
-
Chicago, Illinois, United States, 60611
-
-
Kansas
-
Kansas City, Kansas, United States, 66160
-
-
Kentucky
-
Louisville, Kentucky, United States, 40295
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70121
-
-
Maryland
-
Baltimore, Maryland, United States, 21211
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02120
-
-
Michigan
-
Royal Oak, Michigan, United States, 48073
-
-
Missouri
-
St. Louis, Missouri, United States, 63130
-
-
New Hampshire
-
Lebanon, New Hampshire, United States, 03766
-
-
New York
-
East Syracuse, New York, United States, 13057
-
-
North Carolina
-
Charlotte, North Carolina, United States, 28207
-
Durham, North Carolina, United States, 27708
-
-
Ohio
-
Cincinnati, Ohio, United States, 45219
-
Cleveland, Ohio, United States, 44106
-
Columbus, Ohio, United States, 43210
-
-
Oregon
-
Bend, Oregon, United States, 97701
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19140
-
Pittsburgh, Pennsylvania, United States, 15212
-
Pittsburgh, Pennsylvania, United States, 15213
-
-
South Carolina
-
Charleston, South Carolina, United States, 29406
-
-
Texas
-
Plano, Texas, United States, 75093
-
-
Virginia
-
Charlottesville, Virginia, United States, 22903
-
-
Washington
-
Seattle, Washington, United States, 98122
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Subject is 18 years of age or older
Subject had a spinal procedure where a dural opening (either intentional or incidental) occurred and was treated with either:
- DuraSeal™ Exact Spine Sealant (DuraSeal™ Sealant group ONLY) OR
- Any other method of sealing the dura with the exception of DuraSeal™ Sealant -either spinal or cranial. (Control group ONLY)
Subject, or authorized representative, has been informed of the nature of the study and has provided written informed consent approved by the appropriate Institutional Review Board (IRB) of the respective clinical site prior to the collection of study data.
- Prospective subjects: Consent must be obtained within 24 hours of surgery stop time.
- Retrospective subjects (Control group specific): IRB approval may be granted to individual sites to waive requirement for informed consent.
Exclusion Criteria:
- The investigator determines that the subject will not be able to comply with the required follow-up visits (not required if subject is being enrolled retrospectively- control group ONLY)
- Pregnant or breastfeeding females (as documented in the medical records; no testing beyond the site's standard of care is required)
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Other
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
DuraSeal Arm
Prospective enrollment of subjects who have received DuraSeal Exact Spinal Sealant System for treatment of an intentional or incidental dural tear during spine surgery.
|
DuraSeal Exact Spine Sealant System will be administered to those eligible patients, to treat a dural opening.
|
|
Control Arm
Subjects who have undergone a spinal procedure where techniques other than DuraSeal were administered for the treatment of either an intentional or incidental opening of the dura may be enrolled either prospectively or retrospectively (via medical record screening)
|
Devices or drugs used to seal the dura (other than DuraSeal)
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Post-operative CSF leaks
Time Frame: 90 days post-operative
|
90 days post-operative
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Post-operative surgical site infections
Time Frame: 90 days post-operative
|
Deep surgical site infections as defined by the Center for Disease Control criteria.
|
90 days post-operative
|
|
Post-operative neurological serious adverse events
Time Frame: 90 days post-operative
|
90 days post-operative
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- COVDRSS0002
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.